Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest Æterna Zentaris Stories

2013-05-07 16:29:55

All amounts are in U.S. dollars (unless otherwise noted) QUEBEC CITY, May 7, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"), a late stage drug development company specializing in oncology and endocrinology, today reported financial and operating results as at and for the first quarter ended March 31, 2013. Key Drug Developments AEZS-108 (Doxorubicin Peptide Conjugate) -- First patient treated for Phase 2 trial in...

2013-05-01 08:30:51

QUEBEC CITY, May 1, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") will announce its first quarter 2013 financial and operating results after market close on Tuesday, May 7, 2013. The Company will host a conference call to discuss these results on Wednesday, May 8, 2013, at 8:30 a.m., Eastern Time. Participants may access the live webcast via the Company's website at www.aezsinc.com in the "Newsroom" section, or by telephone using the...

2013-04-23 16:25:34

QUEBEC CITY, April 23, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") newly appointed President and CEO, David A. Dodd will hold an introductory analyst and investor conference call on Thursday, April 25, 2013 at 4:30 p.m., Eastern Time. Participants may access the live webcast via the Company's website at www.aezsinc.com in the "Newsroom" section, or by telephone using the following numbers: in Canada, 514-807-9895 or 647-427-7450,...

2013-04-17 08:29:15

All amounts are in US dollars (unless otherwise mentioned) QUÉBEC CITY, April 17, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that its German subsidiary has entered into binding agreements with various partners and licensees with respect to the manufacturing rights and obligations for its Cetrotide(®) product. The principal effect of such agreements is to transfer manufacturing rights and to grant a...

2013-04-15 08:28:43

QUÉBEC CITY, April 15, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") announced today that David A. Dodd has been appointed President and Chief Executive Officer of the Company, succeeding Juergen Engel, PhD.  Mr. Dodd has also been appointed director on the Company's Board of Directors. Aeterna Zentaris Inc. is an oncology and endocrinology drug development company currently investigating treatments for various unmet...

2013-04-10 16:26:33

QUÉBEC CITY, April 10, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today presented encouraging updated proof-of-concept results for Disorazol Z cytotoxic conjugates, such as AEZS-125 and AEZS-138, in human ovarian and endometrial cancer xenograft models. Results further showed the compounds' high potential for the treatment of luteinizing hormone-releasing hormone ("LHRH") receptor positive tumors. Data were presented...

2013-04-10 08:31:03

All amounts are in US dollars QUÉBEC CITY, April 10, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced the signing of a co-development and profit sharing agreement with Ergomed Clinical Research Ltd. ("Ergomed") for AEZS-108 in endometrial cancer. Ergomed was selected as the contract clinical development organization to conduct the multicenter, multinational, randomized Phase 3 trial with AEZS-108 in...

2013-04-03 08:27:32

QUÉBEC CITY, April 3, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that Babette Aicher, PhD, Director of Preclinical Development, will be making a poster presentation on updated proof-of-concept results for Disorazol Z cytotoxic conjugates, such as AEZS-125 and AEZS-138, in human ovarian and endometrial cancer xenograft models, at the upcoming American Association for Cancer Research ("AACR") annual meeting,...

2013-03-21 16:25:23

All amounts are in U.S. dollars (unless otherwise noted) QUEBEC CITY, March 21, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"), a late-stage drug development company specializing in oncology and endocrinology, today reported financial and operating results as at and for the fourth quarter and the year ended December 31, 2012. Key Developments in 2012 AEZS-108 (Doxorubicin Peptide Conjugate) -- Special Protocol Assessment...

2013-03-12 08:28:38

QUEBEC CITY, March 12, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") will announce its fourth quarter and full-year 2012 financial and operating results on Thursday, March 21, 2013, after market close. The Company will host a conference call the next morning, Friday, March 22, 2013 at 8:30 a.m. (Eastern Time), to discuss these results. Participants may access the live webcast via the Company's website at www.aezsinc.com in the "Newsroom"...